Successful treatment of severe hidradenitis suppurativa with anakinra

JAMA Dermatology

Volumn 149, Issue 10, 2013, Pages 1192-1194

  Zarchi, Kian ^a   Dufour, Deirdre Nathalie ^a   Jemec, Gregor B E ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMOXICILLIN; AZATHIOPRINE; CLAVULANIC ACID; CLINDAMYCIN; CYCLOSPORIN; INFLIXIMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIFAMPICIN;

ADULT; APPLICATION SITE FOLLICULITIS; ARTICLE; CASE REPORT; DERMATITIS; DERMATOLOGY LIFE QUALITY INDEX; DISEASE DURATION; DISEASE SEVERITY; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; HYPERTROPHIC SCAR; INJECTION SITE REACTION; MEDICAL HISTORY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; SKIN FISTULA; SKIN PAIN; SUPPURATION; SUPPURATIVE HIDRADENITIS;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HIDRADENITIS SUPPURATIVA; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84885903355     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.5377     Document Type: Article

References (10)

1. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3): 210-216.
2. Jemec GB. Clinical practice: hidradenitis suppurativa. N Engl J Med. 2012;366(2): 158-164.
3. Kimball AB, Kerdel F, Adams D, et al. Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. 2012;157(12): 846-855.
4. van der Zee HH, de Ruiter L, van den Broecke DG, DikWA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6): 1292-1298.
5. Jemec GB, HeidenheimM, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J AmAcad Dermatol. 1996;35(2, pt 1): 191-194.
6. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87(6): 2095-2147.
7. Mertens M, Singh JA. Anakinra for rheumatoid arthritis: a systematic review. J Rheumatol. 2009;36(6): 1118-1125.
8. Singh JA,Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev. 2011;(2):CD008794. doi: 10.1002/ 14651858.CD008794.pub2.
9. Hsiao JL, Antaya RJ, Berger T, Maurer T, Shinkai K, Leslie KS. Hidradenitis suppurativa and concomitant pyoderma gangrenosum: a case series and literature review. Arch Dermatol. 2010;146(11): 1265-1270.
10. Braun-FalcoM, Kovnerystyy O, Lohse P, Ruzicka T. Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH) - a new autoinflammatory syndrome distinct from PAPA syndrome. J AmAcad Dermatol. 2012;66(3): 409-415.